Trevena, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • TRV250
    • TRV734
    • TRV045
    • TRV027
  • Products
    • OLINVYKâ„¢ (oliceridine) injection
  • Medical Affairs
    • Investigator-Initiated Trials
    • Contact Medical Information
  • Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial Info
    • Stock Info
    • Resources
    • Governance
  • Careers
  • Contact
    • Contact Medical Information
    • Whistleblower Hotline

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
    • Presentations
    • IR Calendar
  • Financial Info
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Stock Info
    • Quote
    • Analyst Coverage
  • Resources
    • Email Alerts
    • Contacts
    • FAQ
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Governance Documents

Trevena Announces Pricing of Initial Public Offering of 9,250,000 Shares of Common Stock

Jan 31, 2014 6:30am EST

Trevena Announces Pricing of Initial Public Offering

Jan 30, 2014 5:34pm EST

Trevena Announces Dosing of First Patient in Phase 2b BLAST-AHF Trial of TRV027 for Acute Heart Failure

Jan 09, 2014 7:00am EST

Trevena Appoints Francois Nader, MD, to its Board of Directors

Jan 08, 2014 7:00am EST

First Clinical Experience of Trevena's lead CNS Biased Ligand, TRV130, Published in Journal of Clinical Pharmacology

Oct 15, 2013 8:00am EDT

Trevena Files Registration Statement for Proposed Initial Public Offering

Oct 10, 2013 7:00am EDT

Trevena Appoints Roberto Cuca as Senior Vice President & Chief Financial Officer

Sep 17, 2013 1:18pm EDT

Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study

Jul 30, 2013 7:00am EDT

Trevena Granted Key Composition of Matter Patent for TRV027 in U.S.

Jul 17, 2013 7:00am EDT

Journal of Clinical Pharmacology Publishes First Clinical Experience with Trevena's Heart Failure Biased Ligand TRV027

Jul 08, 2013 7:00am EDT
RSS
  • Prev
    • 1...
    • 21
    • 22
    • 23
    • 24
    • 25
    • 26
    • 27
    • 28
    • 29
    • 30
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
    © 2022 Trevena, Inc. All Rights Reserved.
    Privacy Policy Terms of Use Disclaimer Sitemap